January 2023 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
Belimumab is a B-lymphocyte stimulator-specific inhibitor.
The sNDA is supported by data from the phase 2 PIONEER trial that evaluated the efficacy and safety of avapritinib in patients with indolent systemic mastocytosis.
The new room temperature storage condition for Asceniv and Bivigam is immediately effective.
The table provided is a review of notable updates that occurred in September 2022 for investigational products in development.
The approval was based on data from an expanded access program which evaluated the safety of amifampridine in 21 pediatric patients for at least 1 year.
Leniolisib is a small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K with immunomodulating and potentially antineoplastic activities.
Risk for maternal IBD relapse and prematurity reduced with continuation of anti-TNF after 24 weeks of pregnancy
Most secondary end points did not support the results of the analysis for the primary end point
Stay up-to-date on the latest drugs in development.